The Supreme Court declined to hear Teva's challenge to a $235 million award to GlaxoSmithKline in a patent dispute over generic drugs involving heart medication Coreg, according to a Reuters report.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results